Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Moertel, C. G.    Kunselman, S.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

The Management of Patients with Advanced Carcinoid Tumors and Islet Cell Carcinomas

Charles G. Moertel; C. Michael Johnson; Michael A. McKusick; J. Kirk Martin; David M. Nagorney; Larry K. Kvols; Joseph Rubin; and Susan Kunselman

15 February 1994 | Volume 120 Issue 4 | Pages 302-309

Objective: To determine the effectiveness of hepatic artery occlusion alone and with sequenced chemotherapy for patients with hepatic-dominant metastases of islet cell carcinomas and carcinoid tumors.

Design: Nonrandomized, observational study with follow-up from 2.5 to 10 years.

Patients: 111 ambulatory patients referred to a multidisciplinary tertiary care center who had histologically proven islet cell carcinoma or carcinoid tumor and symptomatic measurable metastatic lesions in the liver or hormonal abnormalities or both. The patients were ambulatory but were having substantial symptoms because of their endocrine syndromes or their tumors.

Intervention: All patients had hepatic artery occlusion done surgically or by catheterization and embolization. After this procedure, 71 patients were selected for chemotherapy with alternating two-drug regimens of doxorubicin plus dacarbazine and streptozocin plus fluorouracil. Main outcome measures of response to therapy were rates of tumor regression, rates of improvement in endocrine abnormalities, symptomatic improvement, and duration of favorable response.

Results: Objective regressions were observed in 60% of patients treated with occlusion alone and in 80% with chemotherapy added. Regressions were associated with substantial or complete relief from the endocrine syndromes. With occlusion alone, the median duration of regression was 4.0 months and with chemotherapy added, it was 18.0 months. Any comparative inferences about the two treatment regimens must be guarded, because this was not a randomized trial and marked differences occurred in the distribution of prognostic factors between the patient groups. Side effects of arterial occlusion included fever, nausea, pain, and abnormalities in liver function. Side effects of chemotherapy included nausea, vomiting, leukopenia, and alopecia.

Conclusions: Hepatic arterial occlusion can frequently produce major regression of neuroendocrine tumors with relief from the hormonal syndromes. Sequential chemotherapy may improve the rate and duration of the regression.

Author and Article Information

From the Mayo Clinic, Rochester, Minnesota; the Mayo Clinic, Jacksonville, Florida; The Pennsylvania State University, University Park, Pennsylvania.
Requests for Reprints: Charles G. Moertel, MD, Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

This article has been cited by other articles:

				M. J. Steward, V. S. Warbey, A. Malhotra, M. E. Caplin, J. R. Buscombe, and D. Yu Neuroendocrine Tumors: Role of Interventional Radiology in Therapy RadioGraphics, July 1, 2008; 28(4): 1131 - 1145. [Abstract] [Full Text] [PDF]

				M. H Kulke Gastrointestinal neuroendocrine tumors: a role for targeted therapies? Endocr. Relat. Cancer, June 1, 2007; 14(2): 207 - 219. [Abstract] [Full Text] [PDF]

				E. Vilar, R. Salazar, J. Perez-Garcia, J. Cortes, K. Oberg, and J. Tabernero Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors Endocr. Relat. Cancer, June 1, 2007; 14(2): 221 - 232. [Abstract] [Full Text] [PDF]

				A. Markou, P. Manning, B. Kaya, S. N Datta, J. B Bomanji, and G. S Conway [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing's syndrome Eur. J. Endocrinol., April 1, 2005; 152(4): 521 - 525. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]

				J. C. Yao and J.-N. Vauthey Primary and Metastatic Hepatic Carcinoid: Is There an Algorithm? Ann. Surg. Oncol., December 1, 2003; 10(10): 1133 - 1135. [Full Text] [PDF]

				A.N.M. Wymenga, B. Eriksson, P.I. Salmela, M.B. Jacobsen, E.J.D.G. Van Cutsem, R.H. Fiasse, M.J. Valimaki, J. Renstrup, E.G.E. de Vries, and K.E. Oberg Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms J. Clin. Oncol., April 1, 1999; 17(4): 1111 - 1111. [Abstract] [Full Text] [PDF]

				M. H. Kulke and R. J. Mayer Carcinoid Tumors N. Engl. J. Med., March 18, 1999; 340(11): 858 - 868. [Full Text] [PDF]

				F. Yu, D. J. Venzon, J. Serrano, S. U. Goebel, J. L. Doppman, F. Gibril, and R. T. Jensen Prospective Study of the Clinical Course, Prognostic Factors, Causes of Death, and Survival in Patients With Long-Standing Zollinger-Ellison Syndrome J. Clin. Oncol., February 1, 1999; 17(2): 615 - 615. [Abstract] [Full Text] [PDF]

				K. Öberg Carcinoid Tumors: Current Concepts in Diagnosis and Treatment Oncologist, October 1, 1998; 3(5): 339 - 345. [Abstract] [Full Text]

				S B Saslow, J S Scolapio, M Camilleri, L A Forstrom, G M Thomforde, D D Burton, J Rubin, H C Pitot, and A R Zinsmeister Medium term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea Gut, May 1, 1998; 42(5): 628 - 634. [Abstract] [Full Text] [PDF]